ICD-10-CM Code C25.9

Malignant neoplasm of pancreas, unspecified

Version 2020 Billable Code Neoplasm Malignant Primary

Valid for Submission

C25.9 is a billable code used to specify a medical diagnosis of malignant neoplasm of pancreas, unspecified. The code is valid for the year 2020 for the submission of HIPAA-covered transactions. The ICD-10-CM code C25.9 might also be used to specify conditions or terms like adenocarcinoma of pancreas, carcinoma of pancreas, cystadenocarcinoma of pancreas, exocrine pancreas tnm finding, exocrine pancreas tnm finding, exocrine pancreas tnm finding, etc

ICD-10:C25.9
Short Description:Malignant neoplasm of pancreas, unspecified
Long Description:Malignant neoplasm of pancreas, unspecified

Index to Diseases and Injuries

The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10 code(s). The following references for the code C25.9 are found in the index:


Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Adenocarcinoma of pancreas
  • Carcinoma of pancreas
  • Cystadenocarcinoma of pancreas
  • Exocrine pancreas TNM finding
  • Exocrine pancreas TNM finding
  • Exocrine pancreas TNM finding
  • Exocrine pancreas TNM finding
  • Exocrine pancreas TNM finding
  • Exocrine pancreas TNM finding
  • Familial malignant neoplasm of pancreas
  • Invasive intraductal papillary-mucinous carcinoma of pancreas
  • Local recurrence of malignant tumor of pancreas
  • Malignant tumor of pancreas
  • Metastasis from malignant tumor of pancreas
  • pN1a category
  • pN1a: Metastasis in single regional lymph node
  • pN1b category
  • pN1b: Metastasis in multiple regional lymph node
  • Primary adenocarcinoma of pancreas
  • Primary malignant neoplasm of pancreas
  • pT1: Tumor limited to the pancreas, 2 cm or less in greatest dimension
  • pT2: Tumor limited to the pancreas, more than 2 cm in greatest dimension
  • pT3: Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery
  • pT4: Tumor involves the celiac axis or the superior mesenteric artery
  • Serous cystadenocarcinoma of pancreas
  • Squamous cell carcinoma of exocrine pancreas
  • T1: Tumor limited to pancreas and < 2 cm in greatest dimension
  • T2: Tumor limited to pancreas and > 2 cm in greatest dimension
  • T3: Pancreatic tumor extends directly to any of the following: duodenum; bile duct; peripancreatic tissues
  • T4: Pancreas tumor extends directly to any of the following: stomach; spleen; colon; adjacent large vessels
  • Tumor invades beyond pancreatic capsule to adjacent large vessels
  • Tumor invades beyond pancreatic capsule to adjacent structures AND/OR organs
  • Tumor invades beyond pancreatic capsule to bile duct
  • Tumor invades beyond pancreatic capsule to colon
  • Tumor invades beyond pancreatic capsule to duodenum
  • Tumor invades beyond pancreatic capsule to spleen
  • Tumor invades beyond pancreatic capsule to stomach
  • Tumor invades beyond pancreatic capsule, but does not invade adjacent structures AND/OR organs

Diagnostic Related Groups

The ICD-10 code C25.9 is grouped in the following groups for version MS-DRG V37.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC).
applicable from 10/01/2020 through 09/30/2020.

  • 435 - MALIGNANCY OF HEPATOBILIARY SYSTEM OR PANCREAS WITH MCC
  • 436 - MALIGNANCY OF HEPATOBILIARY SYSTEM OR PANCREAS WITH CC
  • 437 - MALIGNANCY OF HEPATOBILIARY SYSTEM OR PANCREAS WITHOUT CC/MCC

Convert C25.9 to ICD-9

  • 157.9 - Malig neo pancreas NOS

Code Classification

  • Neoplasms (C00–D48)
    • Malignant neoplasms of digestive organs (C15-C26)
      • Malignant neoplasm of pancreas (C25)

Code History

  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
    (First year ICD-10-CM implemented into the HIPAA code set)
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020

Table of Neoplasms

The code C25.9 is included in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.

Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.

The Tabular must be reviewed for the complete diagnosis code.

Neoplasm, neoplastic Malignant
Primary
Malignant
Secondary
CaInSitu Benign Uncertain
Behavior
Unspecified
Behavior
»pancreas
C25.9C78.89D01.7D13.6D37.8D49.0

Information for Patients


Pancreatic Cancer

The pancreas is a gland behind your stomach and in front of your spine. It produces the juices that help break down food and the hormones that help control blood sugar levels. Pancreatic cancer usually begins in the cells that produce the juices. Some risk factors for developing pancreatic cancer include

  • Smoking
  • Long-term diabetes
  • Chronic pancreatitis
  • Certain hereditary disorders

Pancreatic cancer is hard to catch early. It doesn't cause symptoms right away. When you do get symptoms, they are often vague or you may not notice them. They include yellowing of the skin and eyes, pain in the abdomen and back, weight loss and fatigue. Also, because the pancreas is hidden behind other organs, health care providers cannot see or feel the tumors during routine exams. Doctors use a physical exam, blood tests, imaging tests, and a biopsy to diagnose it.

Because it is often found late and it spreads quickly, pancreatic cancer can be hard to treat. Possible treatments include surgery, radiation, chemotherapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells.

NIH: National Cancer Institute


[Learn More]